⚠ COVID-19 INFORMATION: Resources, Vaccine Information

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Official Title: Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).

NCT04218851
Muller, William J., MD, PhD
Interventional
Yes

Contact Information:

Laura Fearn, RN

Research Nurse

312.227.6285